Why the study?
Does HMG-CoA reductase inhibition prevent endothelial damage in a human in vivo model of ischemia-reperfusion injury?
Does HMG-CoA reductase inhibition prevent endothelial damage in a human in vivo model of ischemia-reperfusion injury?
HMG-CoA reductase inhibitors protect against ischemia-reperfusion-induced endothelial damage via a COX-2 dependent mechanism, providing a potential mechanistic explanation for their cardioprotective benefits in PCI and CABG.
Answers are grounded in this paper and cite their sources.
Supports COX-2–dependent statin protection in ischemia-reperfusion; leaves open clinical translation to PCI/CABG outcomes.
Animal studies have consistently demonstrated the ability of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors to limit the damage induced by ischemia-reperfusion (IR) in the cardiac, cerebral and mesenteric circulation through a mechanism dependent on the upregulation of cyclooxygenase-2 (COX-2). Our group performed studies aimed at investigating the mechanism of HMG-CoA reductase inhibitor-mediated endothelial protection from IR injury, in particular the role of COX-2, in a human in vivo model of IR-induced endothelial dysfunction. We demonstrated that HMG-CoA reductase inhibition protects against IR-induced endothelial damage, an effect that was lost upon COX-2 inhibition. These observations may suggest a mechanistic explanation for the cardioprotection observed in clinical settings such as percutaneous coronary interventions and coronary artery bypass surgery and may also propose a mechanistic hypothesis for the reported cardiotoxic effects of cyclooxygenase-2 inhibitors observed in clinical studies. These studies are summarized and discussed in the present paper.
No takes yet. Share an insight, caveat, or question.
Liuni et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: